TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01879579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention
Description: Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
Study: NCT04175509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal acetaminophen
Description: Rectal 1300mg
Study: NCT03059979

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: 100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
Study: NCT03432182

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: electroencephalography
Description: Sleep states definition by electroencephalograpy
Study: NCT02748707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm1
Description: Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2
Description: Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 3
Description: Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm 4
Description: Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
Study: NCT00170547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
Study: NCT00830258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium 80 mg tablets
Description: 1 x 80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravachol® 80 mg tablets
Description: 1 x 80 mg
Study: NCT06561906

Intervention type: OTHER
Intervention: Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
Description: Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP

Intervention type: OTHER
Intervention: Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
Description: Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP

Intervention type: OTHER
Intervention: Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
Description: Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP

Intervention type: OTHER
Intervention: Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
Description: Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP
Study: NCT02825160

Intervention type: DRUG
Intervention: Ventavis (Iloprost, BAYQ6256)
Description: The treatment of Ventavis should comply with the local product information
Study: NCT02928185

Intervention type: BEHAVIORAL
Intervention: semi-structured interviews

Intervention type: BEHAVIORAL
Intervention: semi-structured interviews

Intervention type: BEHAVIORAL
Intervention: semi-structured interviews

Intervention type: BEHAVIORAL
Intervention: semi-structured interviews
Study: NCT00835146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200 mg tablets
Description: 1 x 200 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COPEGUS™
Description: 1 x 200 mg, single-dose fasting
Study: NCT04145427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LCD
Description: Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management.
Study: NCT04170283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants will receive zanubrutinib at a dose of 160 mg twice daily (for a total daily dose of 320 mg), or the last dose level received in the BeiGene parent study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants will receive zanubrutinib at a dose of 160 mg twice daily (for a total daily dose of 320 mg), or the last dose level received in the BeiGene parent study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks..
Study: NCT01714895

Intervention type: OTHER
Group type: OTHER
Intervention: High insulin eu-hypoglycemic clamp
Description: Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.

Intervention type: OTHER
Group type: OTHER
Intervention: High insulin eu-hypoglycemic clamp
Description: Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.

Intervention type: OTHER
Group type: OTHER
Intervention: Low insulin eu-hypoglycemic clamp
Description: Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.

Intervention type: OTHER
Group type: OTHER
Intervention: Low insulin eu-hypoglycemic clamp
Description: Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
Study: NCT00031434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
Study: NCT04515095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-only Fasting
Description: Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
Study: NCT04803487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robot-assisted cholecystectomy
Description: cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.

Intervention type: OTHER
Group type: OTHER
Intervention: robot-assisted cholecystectomy
Description: cholecystectomy was performed for patients using the da Vinci surgical robot.
Study: NCT02828449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic education program
Study: NCT01109966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Special Medical Food
Description: Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study \> 500mls/day up to 12 months of age \> 400mls/day between 12 and 18 months of age \> 300mls/day over 18 months of age.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Special Medical Food
Description: Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study \> 500mls/day up to 12 months of age \> 400mls/day between 12 and 18 months of age \> 300mls/day over 18 months of age.
Study: NCT01425086

Intervention type: DEVICE
Intervention: Embrace, PCM, warming blanket
Description: Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment.

Intervention type: DEVICE
Intervention: Embrace, PCM, warming blanket
Description: Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment.
Study: NCT01380782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 200 mg BID oral for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 200 mg BID oral for 28 day cycle
Study: NCT00935012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: Once daily 20 mg oral tafamidis (soft gelatin capsule)
Study: NCT04737863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic retreatment
Description: Root canal retreatment in cases with secondary root canal infection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic retreatment
Description: Root canal retreatment in cases with secondary root canal infection
Study: NCT01885572

Intervention type: DEVICE
Group type: OTHER
Intervention: TiLOOP Bra
Description: Titaniferously coated polypropylene mesh
Study: NCT03867838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compliant support
Description: Participants will be given compliant arm support and their reachable workspace measured
Study: NCT02300935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study: NCT04175509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetaminophen
Description: Intravenous 1000mg
Study: NCT00386971

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: 3 grams daily in liquid form by mouth
Study: NCT01652196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
Study: NCT01421134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: 20, 40, 60 mg, flexible dose, once daily PM 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04311580

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intravesical electromotive administration of mitomycin
Study: NCT01494974

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FP7 Ahmed Glaucoma Drainage Implant
Description: Ahmed Glaucoma Valve model FP7

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FP8 Glaucoma Drainage Implant
Description: Ahmed Glaucoma Valve model FP8
Study: NCT03494192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapula Retraction Exercise Group
Description: physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up.
Study: NCT01652196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE MRI
Description: Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
Study: NCT03494192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapula Retraction +Glenohumeral Rotational Exercise Group
Description: physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up
Study: NCT02082093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine System
Study: NCT01140139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV DNA Vaccine
Description: 0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV DNA Vaccine
Description: 0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV DNA Vaccine
Description: 0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
Study: NCT04242134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coating balloon
Description: Provisional stenting technique with DCB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coating balloon
Description: Provisional stenting technique with DCB
Study: NCT03467945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin/Gliclazide Fixed Combination
Description: Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
Study: NCT00386971

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 oz sweet tasting liquid daily by mouth
Study: NCT03794960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TOL-3021
Description: A plasmid expression vector containing the coding sequences for full-length human proinsulin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TOL-3021 Placebo
Description: TOL-3021 Placebo
Study: NCT02912143

Intervention type: OTHER
Intervention: documentation only
Study: NCT01652196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: f18FDG-PET
Description: 18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET (positron emission tomography)
Description: Correlative studies
Study: NCT03688425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator
Description: Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
Study: NCT02430506

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the identical buffer solution in which AERAS-402 is formulated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
Study: NCT02375022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar and icotinib
Description: Endostar and icotinib are used as combination therapy.
Study: NCT02699775

Intervention type: OTHER
Intervention: Motion Analysis
Description: Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
Study: NCT01144494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine
Description: One drop of brimonidine in each eye three times a day for six weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: Lubricating drops added three times a day for six weeks
Study: NCT04403672

Intervention type: DEVICE
Intervention: performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection
Description: IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A\*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A\*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A\*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A\*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit.

Intervention type: DEVICE
Intervention: performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection
Description: IEDCR uses many different kits for COVID-19 detection. These kits include, (1) A\*Star Fortitute Kit 2 for COVID-19 detection (Singapure), (2) Sansure Biotec Limited (China), (3) ModularDx Kit (TIB Molecular Biology, Germany, and (4) DaAn Kit (China). Among these 2 kits, A\*Star Fortitude Kit 2 has been known as the best kit in IEDCR depending on its performance because it rarely generates false positive or false negative results.~A\*Star Fortitude Kit 2 is used for confirmation of any discordant results for other kits in IEDCR. That is, IEDCR uses A\*Star Fortitude Kit for COVID detection as the Gold Standard. In our case, this is the main reason for the selection of this kit in order to compare the performances of RealDetect™ COVID-19 RT-PCR kit.